혈장분획제제(PDT) 시장 : 제품별, 용도별, 세계 예측(2023-2032년)

Global Plasma Derived Therapy Market will grow at a 7.5% CAGR between 2023 and 2032, owing to the expanding network of plasma collection centers and manufacturing facilities. The continuous growth of these infrastructure elements addresses the escalating demand for plasma-derived therapies. With increased accessibility to plasma, the market experiences a boost in the production of therapeutic products, ensuring a more robust supply chain. This expansion will play a pivotal role in meeting the growing global demand for plasma-derived therapies and will significantly contribute to the market's overall development.

For instance, in 2023, Takeda Pharmaceutical, a Japanese biopharmaceutical company, is constructing a state-of-the-art facility in Osaka, the largest of its kind in Japan, to manufacture plasma-derived therapies (PDTs). This strategic initiative enhances Takeda's manufacturing and supply capabilities, meeting the growing global demand for PDTs and addressing increased patient needs in Japan and beyond. This move marks Takeda's significant contribution to strengthening the plasma-derived therapy market, augmenting production capabilities to meet global demand, and addressing increasing patient needs.

The plasma derived therapy industry is fragmented based on product, application, and region.

The albumin segment will establish a significant market foothold by 2032, fueled by the versatile applications and essential role of albumin in various medical interventions. As a crucial plasma protein with widespread therapeutic uses, including in critical care, surgery, and trauma, albumin will stand out for its indispensable value. With a rising demand for albumin-based therapies, this segment will play a pivotal role in shaping the plasma derived therapy industry outlook.

The plasma derived therapy market size idiopathic/immune thrombocytopenic purpura (ITP) segment will witness substantial growth through 2032, attributed to the escalating incidence of ITP and the growing recognition of plasma-derived therapies as effective interventions. With an increasing focus on addressing autoimmune disorders, particularly ITP, the demand for targeted and reliable therapies is rising. Ongoing advancements in medical research and therapeutic innovation will further position the ITP segment as a key contributor to the expanding landscape of plasma-derived therapies, addressing critical healthcare needs.

Europe will register a notable CAGR during 2023 and 2032 due to its advanced healthcare infrastructure and robust research and development efforts. The rising prevalence of plasma-related disorders adds momentum to this trend. Europe's healthcare landscape, marked by technological advancements and a commitment to medical innovation, underscores its pivotal role in shaping the trajectory of the plasma derived therapy industry, making it a primary contributor to the industry growth and development.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market definition
• 1.2 Base estimates & calculations
• 1.3 Forecast calculation
• 1.1 Covid-19 impact analysis at global level
• 1.2 Data validation
• 1.3 Data sources
  • 1.3.1 Primary
  • 1.3.2 Secondary
    • 1.3.2.1 Paid sources
    • 1.3.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Plasma derived therapy industry 360 degree synopsis, 2018 - 2032
  • 2.1.1 Business trends
  • 2.1.2 Product trends
  • 2.1.3 Application trends
  • 2.1.4 Regional trends

Chapter 3 Plasma Derived Therapy Market Insights

• 3.1 Industry segmentation
• 3.2 Industry landscape, 2018 - 2032 (USD Million)
• 3.3 Industry impact forces
  • 3.3.1 Growth drivers
    • 3.3.1.1 Increasing prevalence of rare diseases
    • 3.3.1.2 Growing demand for advanced therapeutic for treatment of genetic disorders
    • 3.3.1.3 Increase in number of plasma collection centers across the globe
    • 3.3.1.4 Rising adoption of immunoglobulins across the nation
  • 3.3.2 Industry pitfalls and challenges
    • 3.3.2.1 Stringent regulatory policies
• 3.4 Growth potential analysis
  • 3.4.1 By product
  • 3.4.2 By application
• 3.5 COVID-19 impact analysis
• 3.6 Regulatory landscape
  • 3.6.1 U.S.
  • 3.6.2 Europe
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

• 4.1 Introduction
• 4.2 Company matrix analysis, 2022
• 4.3 Competitive analysis of major market players, 2022
• 4.4 Competitive positioning matrix, 2022
• 4.5 Strategic dashboard, 2022

Chapter 5 Plasma Derived Therapy Market Estimates and Forecast, By Product, 2018-2032 (USD Million)

• 5.1 Key trends, by product
• 5.2 Immunoglobulins
• 5.3 Coagulation factors
• 5.4 Albumin
• 5.5 Other products

Chapter 6 Plasma Derived Therapy Market Estimates and Forecast, By Application, 2018-2032 (USD Million)

• 6.1 Key trends, by application
• 6.2 Hemophilia
• 6.3 Primary immunodeficiency diseases
• 6.4 Idiopathic/Immune thrombocytopenic purpura (ITP)
• 6.5 Other applications

Chapter 7 Plasma Derived Therapy Market Estimates and Forecast, By Region, 2018 - 2032 (USD Million)

• 7.1 Key trends, by region
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Rest of Latin America
• 7.6 Middle East & Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE
  • 7.6.4 Rest of Middle East & Africa

Chapter 8 Company Profiles

• 8.1 CSL Behring
• 8.2 Takeda Pharmaceutical Company Limited.
• 8.3 Biotest AG
• 8.4 Octapharma
• 8.5 BPL
• 8.6 ADMA Biologics
• 8.7 Grifols, SA
• 8.8 Kedrion
• 8.9 Kamada Pharmaceuticals.
• 8.10 SK Plasma
• 8.11 Pfizer, Inc.